{"result": "(\"entity\"<|>ASPEN<|>ORGANIZATION<|>The American Society for Parenteral and Enteral Nutrition (ASPEN) provides guidelines for nutritional support in patients, particularly those undergoing surgery or with nutritional deficiencies.)\n##\n(\"entity\"<|>CANCER<|>EVENT<|>Cancer is a disease that may require nutritional support due to the effects of treatment and the disease itself on the patient's nutritional status.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>EVENT<|>Nutritional support refers to the methods and practices used to provide nutrition to patients who cannot eat normally, particularly in the context of cancer treatment.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPLEMENTS<|>ORGANIZATION<|>Nutritional supplements are products intended to enhance the diet, often used in patients with cancer to improve nutritional intake and support recovery.)\n##\n(\"entity\"<|>OMEGA 3<|>ORGANIZATION<|>Omega 3 refers to a type of fatty acid that has anti-inflammatory properties and may help in managing symptoms related to cancer cachexia.)\n##\n(\"entity\"<|>CITOQUINAS<|>ORGANIZATION<|>Cytokines are signaling proteins that can influence inflammation and immune responses, often studied in the context of cancer and nutritional support.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>EVENT<|>Enteral nutrition is a method of delivering nutrients directly into the gastrointestinal tract, often used for patients who cannot eat by mouth.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Parenteral nutrition is a method of providing nutrition intravenously, used when enteral feeding is not possible or sufficient.)\n##\n(\"entity\"<|>ALGORITMOS DE EVALUACIÓN<|>EVENT<|>Evaluation algorithms are systematic methods used to assess nutritional needs and support in patients, particularly those with cancer.)\n##\n(\"entity\"<|>PACIENTE ONCOLÓGICO<|>PERSON<|>Oncological patients are individuals diagnosed with cancer who may require specialized nutritional support due to their condition and treatment.)\n##\n(\"relationship\"<|>ASPEN<|>NUTRITIONAL SUPPORT<|>ASPEN provides guidelines for nutritional support specifically for patients with cancer<|>8)\n##\n(\"relationship\"<|>CANCER<|>NUTRITIONAL SUPPORT<|>Cancer patients often require nutritional support to manage symptoms and maintain health during treatment<|>9)\n##\n(\"relationship\"<|>NUTRITIONAL SUPPORT<|>NUTRICIÓN ENTERAL<|>Enteral nutrition is a form of nutritional support used for patients who cannot eat normally<|>7)\n##\n(\"relationship\"<|>NUTRITIONAL SUPPORT<|>NUTRICIÓN PARENTERAL<|>Parenteral nutrition is another form of nutritional support used when enteral feeding is not possible<|>7)\n##\n(\"relationship\"<|>OMEGA 3<|>CANCER<|>Omega 3 may help manage symptoms related to cancer cachexia<|>6)\n##\n(\"relationship\"<|>CITOQUINAS<|>CANCER<|>Cytokines are involved in the inflammatory response associated with cancer<|>5)\n##\n(\"relationship\"<|>PACIENTE ONCOLÓGICO<|>NUTRICIÓN ENTERAL<|>Oncological patients may require enteral nutrition if they cannot eat by mouth<|>8)\n##\n(\"relationship\"<|>PACIENTE ONCOLÓGICO<|>NUTRICIÓN PARENTERAL<|>Oncological patients may require parenteral nutrition if enteral feeding is insufficient<|>8)\n##\n(\"relationship\"<|>NUTRICIONAL SUPPLEMENTS<|>PACIENTE ONCOLÓGICO<|>Nutritional supplements are often used to support oncological patients' dietary needs<|>7)\n##\n(\"relationship\"<|>ALGORITMOS DE EVALUACIÓN<|>PACIENTE ONCOLÓGICO<|>Evaluation algorithms are used to assess the nutritional needs of oncological patients<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: endaciones dietéticas específicas | · Recomendaciones dietéticas específicas | · Nutrición enteral |\n| · Recomendaciones dietéticas generales | · Control de síntomas | · Control de síntomas | o |\n| · Control de síntomas | | · Dieta hiperproteica | · Nutrición parenteral |\n| | · Recomendaciones dietéticas específicas | · Suplementos nutricionales | |\n| | · Control de síntomas | | |\n| | · Dieta hiperproteica | | |\n\n| Reevaluación a los 15 días | Reevaluación a los 15 días | Reevaluación a los 15 días |\n|----------------------------|----------------------------|----------------------------|\n\n| Estable | Con deterioro | Si mejora | Estable | Con deterioro | Si mejora | Estable |\n|---------|---------------|-----------|---------|---------------|-----------|---------|\n| Control periódico | | Control periódico | | · Nutrición enteral | Suplementos | · Nutrición enteral |\n| | | | | o | nutricionales orales | o |\n| Suplementos nutricionales | Suplementos nutricionales | | | · Nutrición parenteral | y control periódico | · Nutrición parenteral |\n| orales y control periódico | orales y control periódico | | | | | |\n\nAdaptado de Candela CG, Pérez LL, Auñón PZ, Suárez LR, Pére SC, Monzón, et al. Algoritmos de evaluación y tratamiento\nnutricional en el paciente adulto con cáncer. Soporte nutricional en el paciente oncológico. 2004; 265-84.\n\nFigura 1. Algoritmo de soporte nutricional.\n\ny nucleótidos) independientemente del estado nutricional (grado de evidencia A)20, 29.\n\n· La Asociación Americana de Nutrición Enteral y Parenteral (ASPEN), no indica el soporte enteral rutinario en todos los pacientes quirúrgicos. Solo en aquellos moderada o severamente desnutridos, y si se va a mantener al menos durante 7 días33.\n\nPara el resto de los pacientes no quirúrgicos, la NE está indicada en aquellos pacientes desnutridos o en riesgo de desnutrición que no puedan, no quieran, o no deban, comer por vía oral, siempre que se pueda lograr un acceso enteral seguro. Dado que la NE no se considera una medida extraordinaria, las únicas contraindicaciones generales son aquellas derivadas de patología gastrointestinal severa, en las que sea necesario el reposo del tracto digestivo.\n\nLa nutrición enteral se deberá considerar cuando la ingesta del paciente cubre < 60% de sus necesidades energéticas. El empleo de NE ha demostrado menor número de complicaciones y menor coste que el uso de NPT en pacientes con cáncer, por lo que debería ser la ruta preferida de soporte nutricional siempre que sea posible.\n\nSelección de la fórmula\n\nEn general, se emplearán fórmulas poliméricas estándar. Existen estudios que han evaluado la utilización de fórmulas con inmunonutrientes34, que han demostrado beneficios cuando se administran de forma pre y postoperatoria, a pacientes que van a ser sometidos a cirugía35. Se ha observado una reducción de marcadores inflamatorios y una mejoría en los parámetros de respuesta inmune, con disminución de las complicaciones postoperatorias y reducción de la estancia hospitalaria, aunque sin mejorar la supervivencia36.\n\nLa inmunonutrición se refiere a la utilización de nutrientes específicos para lograr un beneficio clínico. Las fórmulas más empleadas contienen una combinación de arginina, ácidos grasos ω-3 y nucleótidos. Tras la publicación de las guías clínicas de la ASPEN en 2009, que recomendaban el uso de fórmulas inmunomoduladoras, varios metanálisis han confirmado el beneficio de su utilización de forma perioperatoria, ya que parecen disminuir la incidencia de complicaciones y la estancia hospitalaria. Sin embargo, limitan su empleo a\n---\nTema 40. Valoración y soporte nutricional en el paciente oncológico 649\n\npacientes malnutridos o que no vayan a poder alimen-\ntarse de forma oral >7 días32.\n\nInmunonutrientes\n\nOmega 3: se ha postulado que por sus propiedades\nantiinflamatorias y de reducción de los niveles de cito-\ncinas, podría tener un papel en la caquexia cancerosa,\nreduciendo la pérdida de peso y promoviendo la recu-\nperación ponderal. Se han realizado numerosos estu-\ndios con resultados contradictorios, por lo que la bi-\nblioteca Cochrane realizó una revisión sistemática\npublicada en 200737. En dicha revisión se concluye que\nno parece haber una mejoría significativa en el trata-\nmiento de síntomas con los suplementos enriquecidos\ncon omega\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}